12:00 AM
 | 
Sep 13, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ONYX-015: Began Phase III testing

Also, ONXX expects to begin a 50-100-patient open-label study in recurrent head and neck cancer patients who have failed chemotherapy, including patients from the control arm of the Phase III trial. The...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >